Protagenic Therapeutics, Inc.\new annual total liabilities
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Total Liabilities Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's total liabilities was $1.0M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.0M | −$4.0M | −79.54% |
| 2025 | 2025-03-31 | $5.0M | — | — |
| 2024 | 2024-12-31 | $942,759 | $287,507 | +43.88% |
| 2023 | 2023-12-31 | $655,252 | −$464,610 | −41.49% |
| 2022 | 2022-12-31 | $1.1M | $1,894 | +0.17% |
| 2021 | 2021-12-31 | $1.1M | −$911,015 | −44.90% |
| 2020 | 2020-12-31 | $2.0M | $552,344 | +37.41% |
| 2019 | 2019-12-31 | $1.5M | $568,872 | +62.67% |
| 2018 | 2018-12-31 | $907,767 | $346,075 | +61.61% |
| 2017 | 2017-12-31 | $561,692 | −$123,165 | −17.98% |
| 2016 | 2016-12-31 | $684,857 | −$207,143 | −23.22% |
| 2015 · Dec 31 | 2015-12-31 | $892,000 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $704,000 | $388,000 | +122.78% |
| 2014 | 2014-06-30 | $316,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly total liabilities
As of Jun 30, 2011
As of Sep 30, 2011
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $1.1M | −$9.4M | −89.75% |
| Q4 2026 | 2026-03-31 | $1.0M | −$4.0M | −79.54% |
| Q3 2026 | 2025-12-31 | $6.8M | $5.9M | +623.81% |
| Q2 2026 | 2025-09-30 | $9.7M | $8.9M | +1129.34% |
| Q1 2026 | 2025-06-30 | $10.5M | $9.8M | +1450.97% |
| Q4 2025 | 2025-03-31 | $5.0M | $4.6M | +1030.26% |
| Q4 2024 | 2024-12-31 | $942,759 | $287,507 | +43.88% |
| Q3 2024 | 2024-09-30 | $789,320 | −$490,786 | −38.34% |
| Q2 2024 | 2024-06-30 | $674,559 | −$830,831 | −55.19% |
| Q1 2024 | 2024-03-31 | $446,095 | −$805,880 | −64.37% |
| Q4 2023 | 2023-12-31 | $655,252 | −$464,610 | −41.49% |
| Q3 2023 | 2023-09-30 | $1.3M | $407,850 | +46.76% |
| Q2 2023 | 2023-06-30 | $1.5M | $748,980 | +99.02% |
| Q1 2023 | 2023-03-31 | $1.3M | $173,270 | +16.06% |
| Q4 2022 | 2022-12-31 | $1.1M | $1,894 | +0.17% |
| Q3 2022 | 2022-09-30 | $872,256 | −$414,250 | −32.20% |
| Q2 2022 | 2022-06-30 | $756,410 | −$507,592 | −40.16% |
| Q1 2022 | 2022-03-31 | $1.1M | −$1.1M | −50.49% |
| Q4 2021 | 2021-12-31 | $1.1M | −$911,015 | −44.90% |
| Q3 2021 | 2021-09-30 | $1.3M | −$736,228 | −36.40% |
| Q2 2021 | 2021-06-30 | $1.3M | −$669,986 | −34.64% |
| Q1 2021 | 2021-03-31 | $2.2M | $806,968 | +58.83% |
| Q4 2020 | 2020-12-31 | $2.0M | $552,344 | +37.41% |
| Q3 2020 | 2020-09-30 | $2.0M | $1.4M | +210.70% |
| Q2 2020 | 2020-06-30 | $1.9M | $1.2M | +165.20% |
| Q1 2020 | 2020-03-31 | $1.4M | $545,170 | +65.95% |
| Q4 2019 | 2019-12-31 | $1.5M | $568,872 | +62.67% |
| Q3 2019 | 2019-09-30 | $651,027 | −$16,391 | −2.46% |
| Q2 2019 | 2019-06-30 | $729,243 | $196,694 | +36.93% |
| Q1 2019 | 2019-03-31 | $826,601 | $322,455 | +63.96% |
| Q4 2018 | 2018-12-31 | $907,767 | $346,075 | +61.61% |
| Q3 2018 | 2018-09-30 | $667,418 | $130,496 | +24.30% |
| Q2 2018 | 2018-06-30 | $532,549 | −$45,589 | −7.89% |
| Q1 2018 | 2018-03-31 | $504,146 | −$88,664 | −14.96% |
| Q4 2017 | 2017-12-31 | $561,692 | −$123,165 | −17.98% |
| Q3 2017 | 2017-09-30 | $536,922 | −$111,403 | −17.18% |
| Q2 2017 | 2017-06-30 | $578,138 | −$24,959 | −4.14% |
| Q1 2017 | 2017-03-31 | $592,810 | −$143,225 | −19.46% |
| Q4 2016 | 2016-12-31 | $684,857 | −$207,143 | −23.22% |
| Q3 2016 | 2016-09-30 | $648,325 | −$118,675 | −15.47% |
| Q2 2016 | 2016-06-30 | $603,097 | −$100,903 | −14.33% |
| Q1 2016 · Mar 31 | 2016-03-31 | $736,035 | $134,035 | +22.26% |
| Q4 2015 · Dec 31 | 2015-12-31 | $892,000 | $303,000 | +51.44% |
| Q1 2016 · Sep 30 | 2015-09-30 | $767,000 | $332,000 | +76.32% |
| Q4 2015 · Jun 30 | 2015-06-30 | $704,000 | $388,000 | +122.78% |
| Q3 2015 | 2015-03-31 | $602,000 | — | — |
| Q2 2015 | 2014-12-31 | $589,000 | — | — |
| Q1 2015 | 2014-09-30 | $435,000 | — | — |
| Q4 2014 | 2014-06-30 | $316,000 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | $19.7M | — | — |
| As of Jun 30, 2011 | 2011-06-30 | $16.1M | — | — |
Protagenic Therapeutics, Inc.\new total liabilities trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's total liabilities increased from $316,000 to $1.0M, a change of $715,479. The latest reported quarter, Q1 2027, shows $1.1M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗